Successful paternity of twins following bone marrow transplantation with busulfan, melphalan and cyclophosphamide conditioning.
A 33-year-old man who had received previous chemotherapy with cytarabine, daunorubicin and mitoxantrone followed by an autologous marrow transplant after conditioning with busulfan, melphalan and cyclophosphamide, fathered sex-mismatched fraternal twins approximately 6 years post-transplant. HLA and DNA analyses showed the probability of paternity to be in excess of 99% for each twin. To our knowledge this represents the first documented case of paternity following conditioning with this combination of marrow ablative agents and the first report of twin paternity following autologous marrow transplantation.
Shepherd
J D
JD
Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver, Canada.
Hoar
D I
DI
Keown
P A
PA
Phillips
G L
GL
D000328:Adult; D018906:Antineoplastic Agents, Alkylating; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D010334:Paternity; D014182:Transplantation, Autologous; D014429:Twins, Dizygotic
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan